French drug maker Sanofi has announced that its injectable diabetes treatment Lyxumia has been approved in Japan.

Lyxumia (lixisenatide) is taken once a day in conjunction with basal insulin by patients who are otherwise not able to control their blood sugar levels.

The drug is the first once-daily glucon-like petide (GLP-1) receptor antagonist, a new class of drugs that increase the incretin effect in patients with type 2 diabetes, to be approved in the Japan.

Japan’s Ministry of Health, Labour and Welfare approved the treatment based on 11 clinical trials involving more than 5,000 patients, which showed Lyxumia had a beneficial impact on blood sugar levels and control, as well as weight loss.

Sanofi senior vice-president for global diabetes Pierre Chancel said: "Lyxumia, as the first GLP-1 receptor agonist approved in Japan for use in combination with basal insulin, will be a valuable new treatment option for many of the country’s six million plus people living with type 2 diabetes.

"The MHLW decision immediately enables the use of Lyxumia, which works in a way that complements basal insulin."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Lyxumia is also approved in Mexico, the European Union and Australia.

Image: Lyumia has been shown to control blood sugar levels 11 clinical trials. Photo: courtesy FreeDigitalPhotos.net.